Módszerek összehasonlítása
Tekintse át a kiválasztott módszereket egymás mellett; az eltérő sorok kiemelve jelennek meg.
| Diabetes Symptom Checklist× | Clarke hipoglikémia-tudatosság kérdőív× | |
|---|---|---|
| Tudományterület | Endokrinológia | Endokrinológia |
| Módszercsalád | Process / pipeline | Process / pipeline |
| Keletkezés éve≠ | 1994 | 1995 |
| Megalkotó≠ | Peta Grootenhuis, Frans Snoek, Rolf Heine, Lex Bouter | William L. Clarke, Don J. Cox, Lois A. Gonder-Frederick |
| Típus≠ | Patient self-report symptom checklist | Patient self-report questionnaire |
| Alapmű≠ | Grootenhuis, P. A., Snoek, F. J., Heine, R. J., & Bouter, L. M. (1994). Development of a type 2 diabetes symptom checklist: A measure of symptom severity. Diabet Med, 11(3), 253-261. DOI ↗ | Clarke, W. L., Cox, D. J., Gonder-Frederick, L. A., Julian, D., Schlundt, D., & Polonsky, W. (1995). Reduced awareness of hypoglycemia in adults with IDDM: A prospective study of hypoglycemic frequency and associated symptoms. Diabetes Care, 18(6), 517-522. DOI ↗ |
| Alternatív nevek≠ | DSC-34 | HAQ, Clarke HAQ, Hypoglycemia Awareness Scale |
| Kapcsolódó | 3 | 3 |
| Összefoglaló≠ | The Diabetes Symptom Checklist is a 34-item patient-reported outcome measure assessing the frequency and burden of symptoms directly related to diabetes and its complications. Developed by Grootenhuis and colleagues in 1994, it captures eight symptom dimensions including hyperglycemic symptoms, hypoglycemic symptoms, fatigue, polyuria, neuropathic pain, and psychological distress. The instrument is used to quantify symptom experience and treatment response across diverse diabetes populations. | The Clarke Hypoglycemia Awareness Questionnaire is an 8-item instrument designed to identify patients with impaired hypoglycemia awareness—a condition in which diabetic patients fail to perceive early warning symptoms of low blood glucose, substantially increasing their risk of severe hypoglycemia. Developed by Clarke and colleagues in 1995, it is the most widely used screening tool for this dangerous complication in type 1 diabetes and in insulin-treated type 2 diabetes populations. |
| ScholarGateAdatkészlet ↗ |
|
|